Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

April 23, 2025 12:37 AM AEST | By Investing

Google News:

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Recent News

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

U.S. Treasury, Commerce secretaries and Trade Representative to meet C...

Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.

The firm issued Overweight ratings on six names, including Gilead Sciences (NASDAQ:GILD), Eli Lilly (NYSE:LLY) and AbbVie (NYSE:ABBV), while assigning Neutral ratings to Amgen (NASDAQ:AMGN), Bristol Myers (NYSE:BMY) Squibb, Pfizer (NYSE:PFE), and Merck (NSE:PROR).

“We would refrain from a blanket sector-wide approach toward Pharma given the wide bifurcation of growth profiles and idiosyncratic exposures to tariffs / taxes, IRA/MFN drug pricing, and hot-button HHS/FDA issues,” analysts wrote in their industry launch report.

Gilead, rated Overweight with a $125 price target, was cited for having a “durable 4%+ CAGR into the mid-2030s,” with additional upside from pipeline developments that could extend the company’s HIV franchise into 2040.

AbbVie, also rated Overweight with a $210 price target, offers what Cantor described as a “combination of offense and defense,” pointing to continued momentum in Rinvoq and Skyrizi.

Analysts also highlighted the company's attractive profile given “the lack of major clinical binary catalyst.”

Meanwhile, Eli Lilly is expected to further consolidate its leadership position in obesity, “driving GLP-1 revenues to $85bn+.”

Cantor also issued Overweight ratings on Vertex (NASDAQ:VRTX), Regeneron (NASDAQ:REGN), and Vaxcyte.

Among the four Neutral-rated stocks, Cantor noted that Amgen faces challenges adding value “given the sizable valuation already assigned to MariTide.”

Meanwhile, Bristol Myers, Pfizer, and Merck are “staring down structural growth challenges and lack visibility on a return to growth” before the end of the decade.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.